Asset Sale Rumors: What Do They Mean for Biogen?

April 12, 2016

On Friday, Reuters reported -- according to sources -- that Biogen is potentially exploring a sale of its hemophilia treatments to increase focus on core therapeutic areas.

The potential sale of hemophilia assets, which have been viewed as unusual fits in the company's broad portfolio, come as Biogen implements its restructuring program announced last October.

Currently, Biogen two FDA-approved hemophilia products -- Alprolix (April 2014) and Eloctate (June 2014).

Some are speculating that Biogen may be setting itself up to acquire or to get acquired -- either planning to use cash from the hemophilia unit sale for its own acquisitions or trying to make itself more attractive as a potential M&A target.

Other sources have said, given the Pfizer-Allergan deal fallout, that Biogen could possibly be acquired by Pfizer or Allergan.

Biogen's new CCO, former Merck exec Michel Vounatsos, takes the wheel as of April 18th.